S-OA-L
Oral Abstracts - Session L - Lymphoma/Multiple Myeloma & Solid Tumor
BMT Tandem "Scientific" Meeting
Texas D (Gaylord Texan)
Chairs:
Hillard M. Lazarus, MD
and
Philippe Armand, MD, PhD
Disclosures:
H. M. Lazarus,
Pluristem, advisor for cell therapy: Advisory Board
Actinium, advisor for 131Iodine radiolabeled monoclonal antibody: Advisory Board and Consultancy
Celgene, advisor for pomalidomide for myelofibrosis and also speakers bureau for lenalidomide and pomalidomide: Consultancy and speakers' bureau
Seattle Genetics, advisor for brentuximab vedotin: Advisory Board
P. Armand,
Nothing To Disclose
Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin Lymphoma In The Brentuximab Vedotin Era
Paolo Anderlini, MD, The University of Texas MD Anderson Cancer Center;
Rima Saliba, PhD, University of Texas, MD Anderson Cancer Center;
Celina Ledesma, BS, University of Texas, MD Anderson Cancer Center;
Christina M Chancoco, University of Texas, MD Anderson Cancer Center;
Tamera R. Alexander, University of Texas, MD Anderson Cancer Center;
Amin M. Alousi, MD, UT MD Anderson Cancer Center;
Chitra Hosing, MD, The University of Texas MD Anderson Cancer Center;
Issa F. Khouri, MD, The University of Texas MD Anderson Cancer Center;
Yago L. Nieto, MD, PhD, University of Texas MD Anderson Cancer Center;
Uday R. Popat, MD, The University of Texas MD Anderson Cancer Center;
Elizabeth J. Shpall, MD, UT MD Anderson Cancer Center;
Michelle A Fanale, MD, University of Texas, MD Anderson Cancer Center;
Yasuhiro Oki, MD, University of Texas, MD Anderson Cancer Center;
Jorge E Romaguera, MD, University of Texas, MD Anderson Cancer Center;
Sattva S. Neelapu, MD, University of Texas, MD Anderson Cancer Center;
Anas Younes, MD, Memorial Sloan-Kettering Cancer Center;
Richard E. Champlin, MD, UT MD Anderson Cancer Center
Radioimmunotherapy-Augmented Nonmyeloablative Allogeneic Transplantation Improves Outcomes for Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Results of an Adjusted Cohort Analysis
Ryan D. Cassaday, MD, University of Washington;
Barry E. Storer, PhD, Fred Hutchinson Cancer Research Center;
Mohamed L. Sorror, MD, MSc, Fred Hutchinson Cancer Research Center (FHCRC);
Brenda M. Sandmaier, MD, Fred Hutchinson Cancer Research Center;
Katherine A. Guthrie, PhD, Fred Hutchinson Cancer Research Center;
Lacey M. Hedin, Fred Hutchinson Cancer Research Center;
Jennifer E. Roden, Fred Hutchinson Cancer Research Center;
Joseph G. Rajendran, MD, University of Washington;
John M. Pagel, MD, PhD, Fred Hutchinson Cancer Research Center;
David G. Maloney, MD, PhD, Fred Hutchinson Cancer Research Center;
Rainer F. Storb, MD, University of Washington;
Oliver W. Press, MD, PhD, Fred Hutchinson Cancer Research Center (FHCRC);
Ajay K. Gopal, MD, Fred Hutchinson Cancer Research Center (FHCRC)
Phase II Trial of Busulfan-Based Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed By Reduced Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma
Yi-Bin Chen, MD, Massachusetts General Hospital;
Shuli Li, Dana-Farber Cancer Institute;
Candice Del Rio, RN, Massachusetts General Hospital;
Jessica Driscoll, NP, Massachusetts General Hospital;
Hossein Sadrzadeh, Massachusetts General Hospital;
Jeremy S. Abramson, Massachusetts General Hospital;
Philippe Armand, MD, PhD, Dana-Farber Cancer Institute;
Jeffrey Barnes, Massachusetts General Hospital;
Corey S. Cutler, MD, Dana-Farber Cancer Institute;
David C. Fisher, Dana-Farber Cancer Institute;
Vincent T. Ho, MD, Dana Farber Cancer Institute;
Ephraim Hochberg, MD, Massachusetts General Hospital;
Steven L. McAfee, MD, Massachusetts General Hospital;
Ronald Takvorian, MD, Massachusetts General Hospital;
Joseph H Antin, MD, Dana-Farber Cancer Institute;
Robert J. Soiffer, MD, Dana-Farber Cancer Institute;
Eric Jacobsen, MD, Dana Farber Cancer Institute
Sustained Suppression of Involved Free Light Chain Predicts Long Term Outcomes in Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation: A Multi-Institutional Study
Robert F. Cornell, MD, Vanderbilt University Medical Center;
Shibani Dogra, MD, The Medical College of Wisconsin;
Ruta Brazauskas, PhD, Medical College of Wisconsin;
Stacey Goodman, MD, Vanderbilt University Medical Center;
Madan H. Jagasia, MD, MBBS, MS, Vanderbilt University Medical Center;
Adetola A. Kassim, MD, MS, Vanderbilt University Medical Center;
Kevin T McDonagh, MD, Vanderbilt University Medical Center;
Bipin N. Savani, MD, Vanderbilt University Medical Center;
Parameswaran N. Hari, MD, MRCP, MS, CIBMTR / Medical College of Wisconsin
High-Throughput Sequencing of Antibody Genes Successfully Identifies Clonal Ig Rearrangements in Multiple Myeloma Patients
Alfred L. Garfall, MD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania;
Eline T Luning Prak, MD, PhD, Perelman School of Medicine, University of Pennsylvania;
Wenzhao Meng, PhD, Perelman School of Medicine, University of Pennsylvania;
Robert Daber, PhD, Perelman School of Medicine, University of Pennsylvania;
Bochao Zhang, Drexel University;
Uri Hershberg, PhD, Drexel University;
Dan T. Vogl, MD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania;
Brendan M. Weiss, MD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania;
Martin Carroll, MD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania;
Edward A. Stadtmauer, MD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania;
Christopher Carlson, PhD, Adaptive Biotechnologies
Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective Analysis in the Rituximab Era
Alberto Mussetti, MD, Universita' degli Studi di Milano;
Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center;
Hugo Castro-Malaspina, M.D., Memorial Sloan-Kettering Cancer Center;
Juliet N. Barker, MBBS, FRACP, Memorial Sloan-Kettering Cancer Center;
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Craig Sauter, MD, Memorial Sloan-Kettering Cancer Center;
Miguel-Angel Perales, MD, Memorial Sloan-Kettering Cancer Center
Allogeneic Hematopoietic Cell Transplant (Allo-HCT) for Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma: The University of Michigan Experience
Attaphol Pawarode, MD, University of Michigan;
Thomas Braun, PhD, University of Michigan;
John Magenau, M.D., University of Michigan;
Sung Won Choi, M.D., University of Michigan;
Carrie L. Kitko, MD, University of Michigan;
Gregory Yanik, MD, University of Michigan;
Steven C. Goldstein, MD, University of Michigan;
Daniel R. Couriel, MD, University of Michigan
Phase I/II Study of Paclitaxel Plus Ifosfamide Followed By High-Dose Paclitaxel, Ifosfamide, and Carboplatin with Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors
Darren R. Feldman, MD, Memorial Sloan-Kettering Cancer Center;
Ilya Glezerman, MD, Memorial Sloan-Kettering Cancer Center;
Sujata Patil, PhD, Memorial Sloan-Kettering Cancer Center;
Lindsay Van Alstine, Memorial Sloan-Kettering Cancer Center;
Dean F Bajorin, MD, Memorial Sloan-Kettering Cancer Center;
Patricia Fischer, Memorial Sloan-Kettering Cancer Center;
Amanda Hughes, Memorial Sloan-Kettering Cancer Center;
Joel Sheinfeld, Memorial Sloan-Kettering Cancer Center;
Manjit Bains, Memorial Sloan-Kettering Cancer Center;
Lilian Reich, MD, PhD, Memorial Sloan-Kettering Cancer Center;
George J Bosl, MD, Memorial Sloan-Kettering Cancer Center;
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Robert J Motzer, MD, Memorial Sloan-Kettering Cancer Center
